DiagnoCure gets rights to additional prostate cancer genes
This article was originally published in Clinica
Executive Summary
DiagnoCure has gained rights to additional prostate cancer genes that could improve the specificity of its previously- acquired PCA3 gene for the disease, which it licensed to Gen-Probe in 2003 for diagnostic applications.